GlaxoSmithKline has signed a multiyear partnership agreement with artificial intelligence-powered pathology company PathAI, according to an April 5 news release.
The partnership will focus on accelerating drug development and scientific research in oncology and non-alcoholic steatohepatitis and will use PathAI's digital pathology tools to do so.
"We look forward to leveraging both PathAI's expertise and models to advance GSK's proprietary AI models and focus on designing better models to deliver improved treatment options for patients with cancer and NASH," said Kim Branson, Global Head of Artificial Intelligence and Machine Learning at GSK said in the release.